MedPath

Rheumatologists and the Requesting of Antinuclear Antibodies (ANA) Tests in Patients With Rheumatologic Complaints

Not Applicable
Completed
Conditions
Rheumatic Diseases
Registration Number
NCT02409251
Lead Sponsor
Sint Maartenskliniek
Brief Summary

The aim of this study is to assess the effect of a simple intervention (a combination of education and feedback) on Antinuclear Antibody (ANA) testing.

This aim was chosen because of the known overuse of many laboratory tests, of which ANA testing is one. As overuse of ANA tests can have negative consequences (both for patients and society), the investigators designed an intervention to see how this would influence Antinuclear Antibody testing by rheumatologists.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
29
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Change from baseline (pre-intervention) % of repeated ANA testing at 12 months (post-intervention)Pre- and post-intervention (both 12 months)

Percentage of patients with ≥1 ANA test in 12 months (pre- or post-intervention period)

Change from baseline (pre-intervention) % of ANA associated diagnoses at 12 months (post-intervention)Pre- and post-intervention (both 12 months)

Percentage of patients, in which an ANA is done during the study period, with final diagnosis of SLE, SSc, PM/DM, MCTD or SS

Change from baseline (pre-intervention) APR variation between rheumatologists at 12 months (post-intervention)Pre- and post-intervention (both 12 months)

Standard deviation around the mean APR, calculated from the APRs of the individual rheumatologists

Change from baseline (pre-intervention) % of positive ANA tests at 12 months (post-intervention)Pre- and post-intervention (both 12 months)

Percentage of ANA tests reported as positive by the local laboratory. ANA tests reported as 'weakly positive' are regarded as negative.

Change from baseline (pre-intervention) ANA/new patient ratio (APR) at 12 months (post-intervention)Pre- and post-intervention (both 12 months)

Number of ANA tests divided by the number of new patients

Change from baseline (pre-intervention) reaching the of target APR at 12 months (post-intervention)Pre- and post-intervention (both 12 months)

Difference (percentage) between the actual APR and the target-APR defined during the intervention

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Sint Maartenskliniek

🇳🇱

Nijmegen, Gelderland, Netherlands

Radboud University Medical Center

🇳🇱

Nijmegen, Netherlands

Maartenskliniek Woerden

🇳🇱

Woerden, Netherlands

Sint Maartenskliniek
🇳🇱Nijmegen, Gelderland, Netherlands

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.